We scan new podcasts and send you the top 5 insights daily.
Susanna Banerjee reported that the RAMP-201 study achieved a 17% response rate in KRAS wild-type tumors, contrasting with historic standard of care response rates of roughly 7%. This activity demonstrates that vertical RAF-MEK clamping combined with FAK inhibition extends benefit beyond the minority of patients carrying KRAS alterations.
While initial response rates are similar between the Avutometinib/Defactinib doublet and single-agent Trametinib, the doublet provides double the progression-free survival (PFS). Its remarkable duration of response (over 30 months) indicates superior long-term disease control.
Despite targeting the KRAS pathway, mutated in ~95% of pancreatic cancers, the pivotal study enrolled all patients regardless of mutation status. This "all-comers" approach simplifies recruitment and, if approved, could lead to a broad label without requiring prerequisite genetic testing, potentially because the drug impacts the entire RAS pathway.
The new drug avutometinib uses a "RAF-MEK clamp" mechanism, blocking two nodes in the RAS pathway simultaneously (RAF and MEK). This dual-inhibition strategy is more effective than single-node targeting because it preempts the cancer cell's adaptive resistance mechanisms, where the pathway reactivates itself in response to upstream blocking.
For BRAF V600E low-grade serous ovarian cancer patients who progress on dabrafenib/trametinib, clinicians can appeal for the KRAS-approved combination avutametinib/defactinib. This strategy is based on evidence of the drug's activity in KRAS wild-type patients, offering a rational off-label option.
Susanna Banerjee noted surprising durable responses during early trials of avutometinib combined with defactinib in patients whose disease had already progressed on MEK or BRAF inhibitors. The RAMP-201 trial permitted prior MEK exposure, demonstrating that simultaneous vertical and parallel pathway inhibition bypasses reactivation.
While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.
In KRAS-mutant low-grade serous ovarian cancer, blocking RAS-RAF-MEK signaling triggers compensatory FAK pathway upregulation as an escape mechanism. Combining the RAF/MEK clamp avutametnib with FAK inhibitor defactinib abrogates this bypass resistance, demonstrating notable activity that recently secured accelerated FDA approval.
Early data for next-generation KRAS G12C inhibitors combined with immunotherapy shows a doubling of both response rate (to ~75%) and progression-free survival compared to the current standard of chemo-immunotherapy. This dramatic improvement suggests these combinations will rapidly become the new standard of care.
The RAMP-201 trial showed the combination of Avutometinib and Defactinib achieved a 25% response rate even in patients who had progressed on or were intolerant of prior single-agent MEK inhibitors. This establishes the doublet as an effective subsequent line of therapy in a resistant population.
The multi-selective RAS inhibitor daraxonrasib may be effective even in patients without RAS mutations because the underlying RAS signaling pathway can be active regardless of mutational status. This suggests the drug's applicability could extend beyond a strictly biomarker-defined population, complicating traditional targeted therapy paradigms.